Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Source: onclive.com
Mark Lanasa News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Lanasa Today - Breaking & Trending Today
FDA to Review Tevimbra Plus Chemo in Gastric Cancers
The Food and Drug Administration has accepted a Biologics License Application for Tevimbra with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: curetoday.com
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA -February 27, 2024 at 06:02 am EST
Application based on results from global Phase 3 RATIONALE-305 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer Prescription...
Source: marketscreener.com
FDA Accepts BLA for First-Line Tislelizumab Plus Chemotherapy in Gastric/GEJ Cancer
The biologics license application for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer has been accepted by the FDA.
Source: onclive.com
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
16.10.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines ... Seite 1
Source: wallstreet-online.de